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ABSTRACT 
Objective: Synthesis, characterization and biological screening of some new 1,6-disubstituted Octahydro-1H-pyrrolo[3,4-b]pyridine Schiff base 
(13a-n) derivatives. 
Methods: The scaffold of Octahydro-1H-pyrrolo [3,4-b]pyridine Schiff bases was prepared, synthesised and screened for their biological activity. 
Results: The structure of newly synthesized compounds was characterized by spectral data and screened for their biological activity like 
antioxidant, antimicrobial, antifungal, and chelating efficacy activities against various bacteria and fungi strains. Screening revealed that several of 
these compounds (13a-n) showed potential biological activity. 
Conclusion: Investigation on newly synthesised 1,6-disubstituted Octahydro-1H-pyrrolo[3,4-b]pyridine Schiff base (13a-n) derivatives for their 
biological activity revealed that some of the compounds showed good antioxidant, chelating and antimicrobial properties. The fact that the newly 
synthesised Schiff bases in this study are chemically related to the current medication and suggests further work is clearly warranted and to be explored. 
Keywords: Octahydro-1h-pyrrolo [3,4-b]pyridine, Schiff base, Moxifloxacin, 8-methoxy fluoroquinolone, DPPH, antioxidants. 
 
INTRODUCTION 
Schiff bases are condensation products of primary amines with 
carbonyl compounds and they were first reported by Schiff in 1864 
[1]. The common structural feature of these compounds is the 
azomethine group with a general formula RHC=N-R1, where R and 
R1 are alkyls, aryl, cycloalkyl or heterocyclic groups which may be 
variously substituted. These compounds are also known as anils, 
imines or azomethines. Several studies showed that the presence of 
a lone pair of electrons in a sp2 hybridized orbital of the nitrogen 
atom of the azomethine group is of considerable chemical and 
biological importance. Because of the relative easiness of 
preparation, synthetic flexibility, and the special property of C=N 
group, versatility of Schiff base ligands and biological, analytical and 
industrial applications of their complexes make further 
investigations in this area highly desirable.  
Nowadays, the research field dealing with Schiff base coordination 
chemistry has expanded enormously. The importance of Schiff base 
complexes for bioinorganic chemistry, biomedical applications, 
supramolecular chemistry, catalysis and material science, separation 
and encapsulation processes, and formation of compounds with 
unusual properties and structures has been well recognized and 
well reviewed [2]. Schiff bases shown excellent biological properties 
like antitumor activity [3], plant growth regulators [4], antimicrobial 
[5], corrosion inhibitor [6], antiviral [7] anticonvulsants [8] 
antifungal [9] and anthelmintic activities [10], antibacterial activity 
[11], herbicidal [12],and in analytical chemistry [13]. 
Moxifloxacin [14] is a novel antibacterial 8-methoxy fluoroquinolone 
derivative which exhibits broad-spectrum activity against gram-
positive and gram-negative microbes as well as anaerobes. Based on 
the study and the literature, moxi floxacin is very photostable and 
does not induce as much phototoxicity compared to other analogues 
of fluoro quinoline drugs [15]. The stability and less photo toxicity is 
due to the seventh position substitution of the fluoroquinolone ring 
by an octahydro-1H-pyrrolo [3,4-b]pyridine moiety and its C-8 
position with a methoxy group [16]. It also reported that the 
substituent effect of different basic moieties dealing with 
pyridobenzoxazines [17], the order of potency of basic substituents 
against mycobacteria (from the highest to the lowest) was 
octahydro-1H-pyrrolo [3,4-b]pyridine>3-aminomethyl pyrrolidines> 
3-aminopyrrolidines>piperazines>3-aminoazetidine>3-amino-
methylazetidine [18]. Diazabicyclo alkanes are important synthetic 
precursors in the preparation of compounds with a variety of 
biomedical applications. For example, derivatives of 3,8-
diazabicyclo[3.2.1]octane and 1,4-diazabicyclo[3.2.2]nonane were 
used as the starting materials for the synthesis of various 
biologically active molecules, including α-7 nicotinic acetylcholine 
receptor agonists, which can be used for the treatment of diseases or 
disorders related to the central nervous system (CNS) and 
peripheral nervous system (PNS) [19]. Adducts of 3,8-
diazabicyclo[3.2.1]octane, 1,4-diazabicyclo[3.2.2]nonane and other 
similar diazabicycles with quinolones resulted in products with 
significant antibacterial activity [20]. 1,4-Diazabicyclo[3.2.2]nonanes 
also serve as precursors in the preparation of [18]F isotope-
containing potential radiotracers for imaging α-7 nicotinic 
acetylcholine receptors [21], whereas 3,10-
diazabicyclo[4.3.1]decane derivatives are used in the synthesis of 
[11]C-labeled serotonin transporter ligands [22]. It is also reported 
that diazobicyclodecane derivatives used for the treatment and/or 
prophylaxis of autoimmune disorders and/or inflammatory 
diseases, cardiovascular diseases, neurodegenerative diseases, 
cancer, respiratory diseases and fibrosis [23]. Also, it is reported 
that 8,10-diazabicyclo[4.3.1]decane derivatives are potent nicotinic 
modulators and may be useful in the treatment of diseases related to 
the cholinergic system of the CNS or PNS [24]. Pyridine-substituted 
3,6-diazabicyclo[3.2.0]heptanes were observed to be selective 
agonists for a4b2 nicotinic acetylcholine receptor [25]. The aza-
bicycle heterocyclic scaffolds are found in chemokine CCR5 receptor 
antagonists and inhibitors of dipeptidyl peptidase IV [26]. The 3,7-
Diazabicyclo[4.3.0]nonan-8-ones are shown to be potential 
nootropic and analgesic drugs [27], antiprotozoal [28] and 
antispasmolytic [29] activities. Following are some of the drugs and 
drugs analogues which contain diazabicyclononane moiety-
Moxifloxacin, BAY3118 [30], Pradofloxacin [31], Pyrido[1,2,3-
d,e][1,3,4] benzoxadiazine derivatives [32], 6,5-pyrrolopiperidine 
derivatives [33],and tetrahydro-1H-pyrrolo[2,3-c]pyridine-
derivatives [34]. 
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The diverse biological activities of octahydropyrrolopyridine or 
diazabicycles, and Schiff base pharmacophores encouraged us to 
envisage the molecular modelling,which possesses both these cores 
in a compact system and to elucidate the potential role of these 
compounds as active biological agents. In view of interest in the 
development of simpler and more convenient synthetic routes for 
achieving the biologically active analogues and in continuation of 
our research interest in functionalization of new tricyclic and 
heterocyclic compounds [35-39]. A series of some new 1,6-
disubstituted Octahydro-1H-pyrrolo[3,4-b]pyridine Schiff bases 
(13a-n) were prepared. 
Introducing potential bioactive chromospheres (Schiff bases) on 
octahydro pyrrolopyridine heterocyclic scaffold (Figure-1) allow us to 
synthesise various octahydro pyrrolopyridine compounds giving rise 
to the variety of compounds, which may be screened for diverse 
biological activity. Substitution at 1 and 6 positions will enable us wide 
molecular manipulations. In finding out new derivatives of 
octahydropyrrolopyridine, in this research paper we report a series of 
new Schiff bases with a potential biological activity resulted from the 
condensation of aryl aldehydes with 2,2'-hexahydro-1H-pyrrolo [3,4-
b] pyridine-1,6(2H)-diyldiacetohydrazide. These compounds may also 
act as valuable ligands. The structures of newly synthesized Schiff 
bases were characterized by physic-chemical and spectral data.  
 
 
Fig. 1: Scaffold of Schiff bases of octahydro-1H-pyrrolo [3, 4-b] 
pyridine 
 
The key intermediate in the present study is octahydro-1H-pyrrolo 
[3,4-b] pyridine (7), which was prepared from quinolinic acid (1) as 
per the known literature [40]. Reacting octahydro-1H-pyrrolo[3,4-
b]pyridine (7) with ethyl bromoacetate gave diethyl 2,2'-hexahydro-
1H-pyrrolo[3,4-b]pyridine-1,6(2H)-diyldiacetate (9), which on 
reaction with hydrazine hydrate gives 2,2'-hexahydro-1H-pyrrolo 
[3,4-b]pyridine-1,6(2H)-diyldiacetohydrazide (10). Hydrazides on 
reaction with different aldehydes yield different Schiff bases (13a-n) 
and the molecules are characterized by their spectral data like IR, 
Mass, NMR spectra. The newly synthesised molecules were studied 
for their antioxidant, metal ion chelating and antimicrobial 
properties. 
MATERIALS AND METHODS 
All chemicals used for the synthesis were of reagent grade and were 
procured from Sigma-Aldrich Chemical Co, Bangalore, SDFCL, 
Mumbai, and the intermediates were prepared as per the known 
literature procedure. 1H and 13
Preparation of Quinolinic anhydride (2) 
C NMR spectra were recorded on 400 
MHz and 100 MHz Varian-AS NMR spectrometer using TMS as an 
internal standard. IR spectra were recorded by using Perkin Elmer 
Spectrum 100 Series FT-IR spectrometer. Mass spectra were 
recorded on Agilent 1200 Series LC/MSD VL system. Melting points 
were determined by using Buchi melting point B-545 instrument 
and are uncorrected. All the reactions were monitored by thin-layer 
chromatography (TLC) using pre-coated silica 60 F254, 0.25 mm 
aluminum plates (Merck). Plates were eluted with appropriate 
solvent systems prepared in the laboratory. The developed plates 
were analyzed under UV 254 nm. 
A solution of acetic anhydride (120 ml) and pyridine-2,3-
dicarboxylic acid (1) (60 g) were heated to reflux for 4 h in an oil 
bath. After completion of the reaction, cooled to 80 °C, distilled off 
excess acetic anhydride completely under vacuum at below 80 °C 
and cooled to room temperature, methylene chloride (60 ml) was 
charged to the distilled residue, stirred for 30 min at 40-45 °C, 
Cooled to 0-5 °C, filtered, washed with dichloromethane dried to get 
the desired compound (2) 
Weight: 48 g; Yield: 90 %; White solid; Mp: 136-137 °C; ESI-MS m/z 
=150. 0 (M+1); 1
Preparation of 6-Benzyl-5H-pyrrolo [3,4-b]pyridine-5,7(6H)-
dione (4) 
H NMR (400 MHz, DMSO-d6) δ 7.92-7.95 (1H, dd), 
8,52-8.54 (1H, dd), 9.13-0.14 (1H, dd). 
A mixture of benzylamine (3) (57.0 g, 0.532 mol) and quinolinic 
anhydride (2) (40 g, 0.268 mol) were heated to 100-105 °C for 6 h. 
After completion of reaction cooled the reaction mass to room 
temperature, quenched with ice water. Stirred the quenched mass 
for 30 min, filtered the precipitated product. The crude product was 
dissolved in ethanol by refluxing and then cooled to crystallize the 
product and filtered, dried in an air oven at 50-60 °C to constant 
weight. 
Weight: 51 g; Yield: 80 %; Off White colored solid; Mp: 154-156 °C; 
ESI-MS m/z = 239.1 (M+1); 1
Preparation of 6-Benzyltetrahydro-1H-pyrrolo[3,4-b]pyridine-
5,7(2H,6H)-dione (5) 
H NMR (400 MHz, DMSO-d6) δ 4.8 (s, 
2H,CH2), 7.25-7.35 (m, 5H, Ar-H), 7.78-7.81 (dd, 1H, Ar-H), 8.31-8.33 
(m, 1H, dd), 899-8.98 (m, 1H, Ar-H). 
6-benzyl-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione (50 g, 0.209 mol) 
in methanol (500 ml) was charged with 5% Pd/C (5 g) under 
nitrogen atmosphere into an autoclave. The reaction vessel was 
evacuated with nitrogen followed by application of hydrogen gas at 
a pressure of 4.0-4.5 kg/cm2
Weight: 35.0 g; Yield: 68 %; Off white semi solid; ESI-MS m/z = 245.2 
(M+1); 
. The reaction mixture was heated at a 
temperature of 55-60 °C for a period of 7 h. After completion of the 
reaction, cooled to ambient temperature, filtered the catalyst 
through hyflo supercel bed. The solvent was completely distilled 
under vacuum at below 45 °C. The residue was crystallized from 
isopropyl ether to get the desired compound (5)  
1
Preparation of 6-Benzyloctahydro-1H-pyrrolo [3, 4-b] pyridine (6) 
H NMR (400 MHz, DMSO-d6) δ 1.46-1.57 (2H, m), 1.75-
1.92(2H, m) 2.66-2.73 (1H, m) 3.18-3.22 (3H, d), 4.17-4.34 (2H, m), 
7.22-7.32(5H, ArH, m), 8.75 (brs, 1H, NH). 
Vitride in toluene (200 g, 0.8735 mol) solution was added to a 
solution of 6-benzyltetrahydro-1H-pyrrolo [3,4-b]pyridine-
5,7(2H,6H)-dione (30 g, 0.1228 mol) in toluene (125 ml) at 0-5 °C. 
The reaction mixture was stirred for 30 min and the temperature 
was raised to 25-30 °C and maintained for 1 h.  
The reaction mixture was further heated to 60-65 °C for 4 h, cooled 
to 0-5 °C followed by the addition of 20% sodium hydroxide 
solution. The reaction mixture was again heated to 55 °C, stirred for 
30 min and the toluene layer was separated, washed with saturated 
sodium chloride solution and distilled off the solvent under vacuum 
at below 60 ° C to get the desired product. 
Weight: 20.0 g; Yield: 75 %; White solid; ESI-MS: m/z = 217.2 (M+1). 
Preparation of Octahydro-1H-pyrrolo [3,4-b]pyridine (7) 
A solution of 8-benzyl-2,8-diazabicyclo[4.3.0]nonane (10 g, 0.04622 
mol) in methanol (100 ml) is charged into an autoclave, added 5% 
Pd/C (1 g). The reaction mass was heated to 55 °C for 4 hrs under 
hydrogen pressure, after completion of the reaction, cooled to 25 °C, 
filtered and washed with methanol (9.0 ml). The solvent was 
distilled off to get the desired product octahydro-1H-pyrrolo [3,4-b] 
pyridine. 
Weight: 5.0 g; Yield: 86 %; Light yellow colored liquid; ESI-MS m/z = 
127.1 (M+1); 1H NMR (400 MHz, DMSO-d6) δ 1.24-1.31 (m, 1H), 
1.35-1.46 (m, 1H), 1.59-1.66 (m, 2H), 1.81-1.89 (m, 1H), 2.21 (brs, 
2H), 2.39-2.45(m, 1H), 2.50-2.57 (m, 1H), 2.63-2.82 (4H, m), 2.95-
2.99 (1H, m).  
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Diethyl 2,2'-hexahydro-1H-pyrrolo [3,4-b] pyridine-1,6(2H)-
diyldiacetate (9) 
A mixture of octahydro-1H-pyrrolo[3,4-b]pyridine (7) (25 g, 0.198 
mol), ethyl bromo acetate (8) (98.69 g, 0.594 mol) and anhydrous 
potassium carbonate (164.14 g, 1.189 mol) in N,N-dimethyl 
formamide (125 ml) was heated to 60-65 °C in water bath for 10 h. 
After completion of the reaction as monitored by TLC, cooled the 
reaction mass, and poured into well-stirred ice-cold water. The 
product was extracted with ethyl acetate, dried with anhydrous 
sodium sulphate, removed solvent by evaporation and purified with 
diisopropyl ether offered Diethyl 2,2'-hexahydro-1H-pyrrolo[3,4-
b]pyridine-1,6(2H)-diyldiacetate (9). 




A mixture of diacetate (9) (30 g, 0.1005 mol) and hydrazine hydrate 
(16 g, 0.40 mol) in ethanol (150 ml) was refluxed for 6 h. After 
completion of the reaction, the excess ethanol was removed by 
distillation, on cooling, crystals of the required products separated, 
which were collected by filtration and drying gave the desired product.  
Weight: 25 g; Yield: 93 %; 1
General method for the Synthesis of Schiff bases 
H NMR (400 MHz, DMSO-d6) δ 1.397-
1.554 (4H, m), 1.602-1.745 (1H,m), 2.17-2.228 (2H, m), 2,593-2,563 
(2H, m), 2.675-2.835 (5H, m), 2.993-3.513 (2H, m), 3.04-3.829 (4H, 
brs,), 8.929 (s, 2H) (Amide);  
A solution of diacetohydrazide (11) (1.849 m. mol), different aldehydes 
(12a-n) (3.72 m. mol) and acetic acid (1 ml) in ethanol (50 ml) was 
refluxed for 6 h. After completion of reaction, cooled the reaction mass to 
25-30 °C, quenched with ice water, extracted the product into ethyl 
acetate, after evaporation of solvent and crystallization from diisopropyl 
ether gave corresponding Schiff bases (13a-n). 
[6-(Benzylidene-hydrazinocarbonylmethyl)-octahydro-pyrrolo 
[3,4-b]pyridin-1-yl]-acetic acid benzylidene-hydrazide (13a) 
Yield 75%; Off white solid; MS (ESI) m/z 447.3 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.23-1.25 (2H, m), 1.47-1.49 (2H, m), 1.56-
1.59(1H, m), 1.72-1,91 (2H, m), 2.29-2.46 (1H, m), 2.71-2.86 (2H, m), 
2.90-3.06 (2H, m), 3.08-3.10 (2H, m), 3.17-3.28 (2H, m), 7.37-7.50 
(6H, m, ArH), 7.61-7.71 (4H, m, ArH), 7.96-8.01 (1H, m, ArH), 8.25-





3423, 2933, 1686, 1267 
Yield 70%; Off white solid; MS (ESI) m/z 503.3 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.04-1.21 (6H, m), 1.32-1.46 (4H, m), 1.88-1.99 
(2H,m), 2.51-2.88 (6H, m), 2.96-3.62 (6H, m), 7.15-7.32 (5H, m, ArH), 
7.36-7.50(1H, m, ArH), 7.67-7.81 (2H, m), 8.33-8.35 (1H, m), 8.67-





2962, 1682, 1290, 756; 
Yield 72 %; Off white solid; MS (ESI) m/z 475.3 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.45-1.75 (4H, m), 2.37-2.33 (8H, m), 2.67-2.97 
(6H,m), 3.07-3.23 (3H, m), 3.58-3.68 (1H, m), 7.15-7.32 (5H, m, ArH), 
7.36-7.50 (1H, m, ArH), 7.67-7.81 (2H, m), 8.33-8.35 (1H, m), 8.67-





2962, 1682, 1290, 756; 
Yield 67%; Off white solid; MS (ESI) m/z: 507.3 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.458-1.599 (4H,m), 1.695-1.750 (1H, m), 2.277-
2.305 (2H, m), 2.334 (6H, S), 2.675-3.073 (6H, m), 3.168-3.339 (2H, 
m), 4.024-4.223 (1H, m), 7.153-7.70 (4H, m, ArH), 7.488-7.574 (4H, 
m, ArH), 7.949-7.995 (1H, m, ArH), 8.220-8.367 (1H, m, ArH), 




 3422, 2956, 1685, 
1250. 
Yield 70%; Off white solid; MS (ESI) m/z: 517.1 (M+1);1H NMR (400 
MHz, DMSO-d6) δ 1.23-1.75 (4H, m), 2.25-2.67 (2H, m), 2.71-3.00 
(6H, m), 3.13-3.44(2H, m), 3.55-3.61(1H, m), 3.70-4.09(1H,m), 7.39-
7.51(4H, m, ArH), 7.59-7.70(4H, m, ArH), 7.94-7.99 (1H, m, ArH), 





3447, 2935, 1697, 1246. 
Yield 70%; Off white solid; MS (ESI) m/z 483.2(M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.49-1.75(4H,m), 2.31-2.50(2H, m), 2.73-3.03(6H, 
m), 3.05,3.38(2H, m), 3.40-3.61(1H, m), 3.66-4.07(1H,m), 7.17-
7.29(4H,m), 7.63-7.76(4H,m), 7.95-8.00(1H, m), 8.25-




 3443, 2930, 1692, 
1250. 
Yield 55 %; Off white solid; MS (ESI) m/z 579.1 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.463-1.709(4H,m), 2.26-2.36(2H,m), 2.67-
3.07(6H, m), 3.17-3.30(2H, m), 3.41-3.56(1H,m), 4.00-4.14(1H,m), 
6.92-6.96(2H,m), 7.21-7.29(2H,m), 7.49-7.56(1H,m), 7.60-
7.63(1H,m), 8.20-8.25(1H,m), 8.46-8.58(1H,m), 11.37 (2H, Brs), 
11.62 (2H,Brs); IR (KBr) ν/cm-1
[6-(3,4,5-Trimethoxy-benzylidene-hydrazinocarbonylmethyl)-
octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (3,4,5-tri 
methoxy-benzylidene)-hydrazide (13h) 
 3433, 3213, 2935, 1690, 1560, 1271. 
Yield 52 %; Off white solid; MS (ESI) m/z 627.3 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.23-1.87(4H,m), 2.31-2.33(2H,m), 2.73-
3.03(8H,m), 3.14-3.42(2H,m), 3.66-3.99(18H,m), 6.89-6.96(4H,m), 





3225, 2940, 1677, 1573, 1235; 
Yield 45%; Off white solid; MS (ESI) m/z 517.2 (M), 519.1 (M+2);1H 
NMR (400 MHz, DMSO-d6) δ 1.23-1.46(2H,m), 2.19-2.44(3H,m), 
2.63-2.86(4H,m), 2.94-3.24(3H,m), 3.29-3.52(2H,m), 3.58-
3.91(2H,m), 7.40-7.53(2H,m), 8.21-8.30(3H,m), 8.40-8.43(1H,m), 




 3418, 2931, 1694, 1557, 1398; 
Yield 63%; Off white solid; MS (ESI) m/z 539.1 (M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.45-1.70(4H,m), 2.29-2.36(2H,m), 2.69-
3.00(7H,m), 3.15-3.39(3H,m), 3.69-3.86(8H,m), 6.78-6.85(2H,m), 
6.96-7.06(2H,m), 7.19-7.24(2H,m), 7.81-7.85(1H,m), 8.13-8.18 
(1H,m), 11.18(2H,brs); 13C NMR (100 MHz, DMSO-d6) δ 21.87, 23.54, 
23,54, 37.30, 51.66, 52.23, 54.75, 54.96, 55.52, 58.74, 62.42, 108.81, 
109.06, 115.43, 120.80, 121.93, 122.03, 122.22, 125.35, 125.50, 





 3430, 2937, 1647, 1550, 1370; 
Yield 56%; Off white solid; MS (ESI) m/z 549.2(M+1); 1H NMR (400 
MHz, DMSO-d6) δ 1.48-1.56(4H,m), 2.32-2.66(2H,m), 2.71-
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2.81(3H,m), 2.90-3.12(4H,m), 3.18-3.62(3H,m), 7.48(2H,brs), 8.06-
8.22(2H,d), 8.66-8.67(2H,d), 11.80(2H,brs); 13C NMR (100 MHz, 
DMSO-d6) δ 22.28, 23.83, 37.69, 48.97, 52.01, 54.91, 57.88, 58.23, 
65.53, 129.34, 129.79, 130.84, 140.69, 141.27, 147.11, 15.07, 167.76, 





Yield 45%; Off white solid; MS (ESI) m/z 455.3 (M+1)); 1H NMR (400 
MHz, DMSO-d6) δ 1.46-1.69 (4H, m), 2.27-2.33 (2H, m), 2.67-2.95 
(6H, m), 3.00-3.11 (1H, m), 3.17-3.28 (1H, m), 3.32-3.50 (1H, m), 
3.58-3.81 (1H, m), 3.82-3.90 (6H, m), 7.69-7.70 (2H, m), 7.95-8.05 
(2H, m), 8.15 (s, 1H), 8.24 (1H, s), 11.03-11.15 (2H, bs); 13C NMR 
(100 MHz, DMSO-d6) δ 21.83, 22.97, 23.40, 37.19 (2methyl C), 
51.31, 54.67, 55.45, 56.11, 58.96, 62.22, 117.31, 117.34, 130.55, 
130.55, 136.46, 137.07, 141.00, 141.04, 171.00, 173.61; IR (KBr) 




Yield 65%; Off white solid; MS (ESI) m/z 667.3 (M+1); 1H NMR 
(400 MHz, DMSO-d6) δ 1.36-1.72(4H, m), 2.18-2.31(2H, m), 2.61-
2.77(3H, m), 2.82-2.99 (3H, m), 3.03-3.24 (2H, m), 3.29-3.55 (1H, 
m), 3.71-3.84 (1H, m), 6.99-7.07 (4H, m), 7.08-7.18 (2H, m), 
7.36-7.46 (8H, m), 7.47-7.50 (2H, m), 7.94-7.98 (1H, m), 8.26-
8.36 (1H, m), 11.48-11.54 (2H, m); 13C NMR (100 MHz, DMSO-
d6) δ 22.0, 23.71, 37.62, 48.98, 51.93, 52.34, 55.98, 58.61, 59.16, 
117.40, 117.54, 117.82, 118.14, 118.37, 118.88, 119.21, 119.87, 
123.95, 124.86, 125.05, 130.59, 132.37, 141.78, 143.47, 143.79, 
145.69, 146.17, 153.43, 155.93, 156.79, 156.98, 167.18, 167.60, 
167.87, 167.00, 171.97, 173.10; IR (KBr) ν/cm-13424, 2939, 
1690, 1584, 1276; 
[6-(4-Fluoro-3-trifluoromethyl-benzylidene-hydrazinocarbonyl 
methyl)-octahydro-pyrrolo [3,4-b]pyridin-1-yl]-acetic acid (4-
fluoro-3-trifluoromethyl-benzylidene)-hydrazide (13n)  
Yield 55%; Off white solid; MS (ESI) m/z 619.2.3 (m+1); 1H NMR 
(400 MHz, DMSO-d6) δ 1.46-1.69 (4H, m), 2.27-2.33 (2H, m), 2.67-
2.95 (6H, m), 3.00-3.11 (1H, m), 3.17-3.28 (1H, m), 3.32-3.50 (1H, 
m), 3.58-3.81 (1H, m), 3.82-3.90 (6H, m), 7.69-7.70 (2H, m), 7.95-
8.05 (2H, m), 8.15 (s, 1H), 8.24 (1H, s), 11.03-11.15 (2H, bs); 13C 
NMR (100 MHz, DMSO-d6) δ 21.83, 22.97, 23.40, 37.19 (2methyl C), 
51.31, 54.67, 55.45, 56.11, 58.96, 62.22, 117.31, 117.34, 130.55, 
130.55, 136.46, 137.07, 141.00, 141.04, 171.00, 173.61; IR (KBr) 
ν/cm-1
Biological activity 
 3419, 2930, 1682, 1576, 1290; 
Antioxidant activity  
The antioxidant activity of novel Schiff bases (13a-n) were determined 
by DPPH scavenging activity method as described by Brand-Williams 
et al., [41] with some modifications. This assay is based on the 
determination of the concentration of 2, 2-diphenyl-1-picrylhydrazyl 
(DPPH) in methanolic solution, after adding the antioxidants, DPPH 
concentration is reduced by the existence of an antioxidant at 515 nm 
and the absorption gradually disappears with time. UV/VIS 
spectrophotometer was used to determine the antioxidant activity of 
each sample. A stock solution (1 mg/ml) of the test compounds was 
prepared in methanol. 100 µl of the compounds were added to 3 ml of 
a 0.004% methanol solution of DPPH radical. After 30 min of 
incubation in the dark at room temperature, the absorbance was 
observed against a blank at 515 nm. Butylated hydroxy toluene (BHT) 
was used as reference standard for comparison. All the experiments 
were carried out triplicate, average and the standard deviations were 
calculated. The percentage of inhibition was calculated using following 
formula and reported in Table-1 
% 𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝐼𝐼 =
𝐴𝐴0 − 𝐴𝐴1 
𝐴𝐴0
𝑋𝑋100 
Where A0 is the absorbance of the control reaction and A1 is the 
absorbance of the sample. 
Metal ion chelating assay 
The ability of samples to chelate iron (II) ion was estimated using the 
method reported by Dinis et al., [42] and compared with that of the 
reference chelator agent EDTA. Test samples of (13a-n) 100 μg 
concentration (1.0 ml) was added to a solution of 2 m. mol 
iron(II)chloride (0.05 ml). The reaction was initiated by the addition of 
5 m. mol ferrozine (0.2 ml) and the volume of the mixture were finally 
adjusted to 3 ml with methanol, shaken vigorously and left standing at 
room temperature for 10 min. After the mixture had reached 
equilibrium, the absorbance of the solution was measured 
spectrophotometrically at 562 nm. All the experiments were carried 
out in triplicate, average and standard deviations was calculated. The 
percentage of inhibition of ferrozine–Fe2+complex formation was 
calculated using the formula given below and reported in Table-2 
% 𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝐼𝐼 =
𝐴𝐴0 − (𝐴𝐴1 − 𝐴𝐴2)
𝐴𝐴0
𝑋𝑋 100 
Where A0 is the absorbance of the control, containing iron (II) 
chloride and ferrozine only, A1 is the absorbance in the presence of 
the tested sample and A2 is the absorbance of the sample under 
identical conditions as A1 with water instead of iron (II) chloride 
solution. 
 
Table 1: Antioxidant activity of Schiff bases (13a-n) 
S. No. Compound Name % of inhibition 
1 13a 64.03±0.15 
2 13b 63.20±0.06 
3 13c 59.77±0.38 
4 13d 23.13±0.81 
5 13e 17.37±0.61 
6 13f 29.67±0.35 
7 13g 30.30±0.82 
8 13h 15.70±0.20 
9 13i 22.50±0.50 
10 13j 89.90±0.52 
11 13k 19.33±0.35 
12 13l 51.33±0.58 
13 13m 43.97±0.95 
14 13n 35.30±1.13 
15 BHT 90.53±1.29 
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Table 2: Metal chelating activity of Schiff bases (13a-n) 
S. No. Compound name % of inhibition 
1 13a 87.33±2.52 
2 13b 84.33±1.26 
3 13c 69.33±0.58 
4 13d -------- 
5 13e 34.60±1.35 
6 13f 87.42±0.40 
7 13g 24.67±1.53 
8 13h ------- 
9 13i ------- 
10 13j 36.17±0.15 
11 13k 45.33±0.81 
12 13l ------- 
13 13m ------- 
14 13n 20.07±0.90 
15 EDTA 87.30±0.26 
 
Antimicrobial activity 
The antibacterial activities of (13a-n) were determined by the well 
plate method using Mueller-Hinton Agar [43]. The in vitro 
antibacterial activity was carried out using 24 h old bacterial 
cultures. In this present work B. subtilis, E. coli and P. aeruginosa 
bacterial strain was used to investigate the activity. The test 
compounds (13a-n) and standard (Streptomycin) were dissolved in 
dimethyl sulfoxide (DMSO) at different concentrations. Twenty ml of 
sterilized agar media was poured into each pre-sterilized Petri dish. 
About 60 µl of bacterial culture suspension were poured and 
swabbed with the pre-sterilized cotton swabs. Six mm diameter well 
were then punched carefully using a sterile cork borer and 60 µl of 
test solution of different concentration were added into each labeled 
well. The plates were incubated for 24 h at 37 °C.  
The inhibition zone around the well in each plate was measured in 
mm. experiments were in triplicates, average and standard deviations 
were calculated. The antimicrobial results were compared with 
Streptomycin as standard and summarized in table 3. 
 
Table 3: Antimicrobial activity of Schiff bases (13a-n) 




Escherichia coli Bacillus subtilis Pseudomonas aeruginosa 
1 0.5 1 0.5 1 0.5 
Streptomycin 19.63±0.32 17.57±0.60 22.43±0.40 19.17±0.29 19.43±0.40 15.20±0.35 
Control 0 0 0 0 0 0 
13a 13.37±0.32 9.43±0.40 10.73±0.64 8.33±0.29 13.17±0.29 10.50±0.50 
13b 15.50±0.50 13.83±0.76 13.77±0.55 11.43±0.40 14.57±0.60 12.17±0.29 
13c 12.53±0.32 9.33±0.58 11.2±0.35 9.83±0.76 13.23±0.40 11.50±0.50 
13d 18.50±0.50 15.73±0.64 15.23±0.40 12.47±0.45 18.33±0.58 16.17±0.29 
13e 17.70±0.75 15.67±0.58 15.27±0.46 12.3±0.26 18.17±0.29 15.67±0.76 
13f NA NA NA NA NA NA 
13g 15.17±0.15 12.17±0,29 15.43±0.75 11.20±0.35 16.17±0.29 14.27±0.46 
13h 14.07±0.12 13.5±0.5 12.4±0.69 10.83±0.76 15.17±0.29 12.90±0.85 
13i NA NA NA NA NA NA 
13j NA NA NA NA NA NA 
13k 18.40±0.36 16.03±0.47 17.63±0.71 15.33±0.58 19.17±0.29 17.53±0.50 
13l NA NA NA NA NA NA 
13m NA NA NA NA NA NA 
13n 16.67±0.47 14.83±0.76 15.3±0.36 13.47±0.45 16.83±0.76 13.67±0.58 
Note: NA-no activity 
 
RESULTS AND DISCUSSION 
Chemistry 
The key starting material octahydro-1H-pyrrolo [3,4-b]pyridine (7) 
was prepared from the known literature method using the scheme-1.  
In an effort to develop the synthesis of novel fused heterocyclic 
compound Schiff bases containing octahydro-1H-pyrrolo [3,4-
b]pyridine ring, a synthetic approach was done and is depicted in 
Scheme 2 and Scheme-3 
Reacting quinolinic acid (1) with acetic anhydride followed by 
treatment with benzyl amine gives N-benzylquinolinic acid imide (4), 
which on reduction with palladium carbon yields 8-benzyl-7,9-dione-
2,8-diazabicyclo[4.3.0]nonane (5), further on reduction with sodium 
bis(2-methoxyethoxy)aluminum-hydride (Vitride) to form 8-benzyl-
2,8-diazabicyclo[4.3.0]nonane (6). This after resolution and followed 
by debenzylation gave octahydro-1H-pyrrolo [3,4-b]pyridine (7). 
 
Scheme 1: Synthetic scheme for the preparation of octahydro-
1H-pyrrolo [3,4-b]pyridine 
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Sheme 2: Synthetic scheme for the preparation of hydrazides (11) 
 
 
Scheme 3: Synthetic scheme for the preparation of Schiff bases 
(13a-n) 
 
Octahydro-1H-pyrrolo[3,4-b]pyridine was reacted with ethyl 
bromoacetate to give diester (8) compound which on reaction with 
hydrazine hydrate and further with several aldehydes gives different 
Schiff bases (13a-n).  
The structures of newly synthesized compounds (13a-n) were 
confirmed by the mass, IR and NMR analysis. The mass spectrum 
shows the prominent ion peak at m/z (M+1). The IR spectrum of 
compounds (13a-n) shows NH and-C=O functional group at around 
3100 cm-1 and 1700 cm-1 and C=N function at around 1200 cm-1. 
The NMR spectrum of compounds (13a-n) shows NH protons at 
around 11.5 ppm.  
Biological study 
Various symmetrical and unsymmetrical bis Schiff bases have been 
well reported by several authors for their antimicrobial, antioxidant 
and chelating activities [44-46]. They showed very good activity 
against various microbes. In this research article, we reporting 
symmetrical Schiff bases of octahydro-1H-pyrrolo [3,4-b]pyridine 
and their biological activities. The antimicrobial activity of the 
octahydro-1H-pyrrolo[3,4-b]pyridine derivatives has been well 
reported for the fluoro quinoline drugs like moxifloxacin and 
pradofloxacinand showed very good activity against gram positive 
and gram negative bacteria. Moxifloxacin is a synthetic broad 
spectrum antibacterial agent, employed for the treatment of 
respiratory infections (pneumonia, chronic sinusitis, and chronic 
bronchitis), skin and soft tissues. Pradofloxacin is a broad-spectrum 
fluoroquinolone and, like moxifloxacin, has enhanced activity 
against gram-positive bacteria relative to narrow-and extended-
spectrum compounds and good activity against anaerobes. It has 
been exclusively developed for use in veterinary medicine. The 
increased potency of pradofloxacin is mainly attributed to the 
octahydro-1H-pyrrolo [3,4-b]pyridine moiety at C-7. The 
antioxidant, metal ion chelating and antimicrobial properties of all 
the newly synthesized compounds (13a-n) was determined by 
known methods.  
Antioxidant activity  
The antioxidant activity of novel Schiff bases (13a-n) was 
determined by DPPH scavenging activity method as described by 
Brand-Williams et al., with some modifications. This assay is based 
on the determination of the concentration of 2, 2-diphenyl-1-
picrylhydrazyl (DPPH) in methanolic solution, after adding the 
antioxidants. DPPH concentration is reduced by the existence of an 
antioxidant at 515 nm and the absorption gradually disappears with 
time. UV/VIS spectrophotometer was used to determine the 
antioxidant activity of each sample. 
The antioxidant activities of newly synthesised compounds (13a-n) 
were determined by DPPH method and were compared with 
reference standard butylated hydroxyl toluene (BHT). The results 
show that the compound (13j) was acts as a good antioxidant. The 
compounds13j substituted with hydroxyl and methoxy functional 
group showed good antioxidant activity, while the other showed a 
week or no activity. 
Metal ion chelating assay 
The ability of samples to chelate iron (II) ion was estimated using 
the method reported by Diniset al. The metal chelating activity of 
newly synthesised compounds (13a-n) was determined and 
compared with reference standard ethylenediaminetetraacetic acid 
(EDTA). Compounds like 13a, 13b, 13f showed good chelating 
activity. While the other showed less or no activity. 
Antimicrobial activity 
All the synthesized compounds (13a-n) were screened for their 
antibacterial activity against B. subtilis, E. coli and P. aeruginosa bacterial 
strain. Minimum inhibitory concentration (MIC) of all compounds was 
determined, which is defined as the lowest concentration of inhibitor at 
which bacterial growth was not visually apparent. 
Investigation on antibacterial screening data (table 1) showed some 
of the compounds were active against three human pathogenic 
bacteria. The antibacterial activities of (13a-n) were determined by 
the well plate method using Mueller-Hinton Agar. The compound 
substituted with13d, 13e, 13k, and 13n showed good activity against 
E. Coli bacteria. The compounds substituted with 13k showed good 
activity against B. substitulis. Compounds substituted with 13d, 13e, 
and 13k showed excellent activity against P. Aeruginosa while the 
other showed no or moderate activity.  
CONCLUSION 
In this article, we report the synthesis of certain Schiff Bases of 
Octahydro-1H-pyrrolo [3,4-b]pyridine derivatives (13a-n), starting 
from commercially available quinolinic acid and characterized by 
spectral data. An investigation of their biological activity revealed 
that some compounds showed good antioxidant, chelating and 
antimicrobial properties. Compound 13j showed good antioxidant 
activity while compounds13a, 13b, and 13f showed good chelating 
agents, the compounds13d and 13k showed good antimicrobial 
activity against the tested pharmacological activity. The fact that the 
newly synthesised Schiff bases in this study are chemically related to 
the current medication suggests that the further work is clearly 
warranted and to be explored. 
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